Effect of immunostimulatory RNA on the fibrosis development in Bleomycin- or LPS-induced mouse models

Standard

Effect of immunostimulatory RNA on the fibrosis development in Bleomycin- or LPS-induced mouse models. / Sen'kova, Aleksandra V.; Bishani, Ali; Savin, Innokenty A. et al.

In: Biochimie, 2024.

Research output: Contribution to journal › Article › peer-review

BibTeX

@article{2a77a003e6c74e938346f18f466bbef2,

title = "Effect of immunostimulatory RNA on the fibrosis development in Bleomycin- or LPS-induced mouse models",

abstract = "Previously, we described a 19-base pair double-stranded RNA with 3′-trinucleotide overhangs, acting as immunostimulatory RNA (isRNA). This molecule demonstrated notable antiproliferative effects on cancer cells, inhibited tumor growth, and elicited immunostimulatory and antiviral responses by inducing cytokine and interferon production. Within this study, we compared the efficiency of lung fibrosis development, initiated in mice by BLM or LPS using different schemes of induction. Then we compared the effect of isRNA used in a preventive or therapeutic regimen on the development of fibrosis in selected BLM- and LPS-induced mouse models and showed that isRNA can be used in pathological conditions accompanied by the development of inflammation and the risk of fibrosis formation, without adverse side effects. Prophylactic regimen of isRNA application is beneficial for prevention of the development of pulmonary fibrosis.",

keywords = "Bleomycine, Immunostimulatory RNA, Inflammation, LPS, Pulmonary fibrosis",

author = "Sen'kova, {Aleksandra V.} and Ali Bishani and Savin, {Innokenty A.} and Zenkova, {Marina A.} and Chernolovskaya, {Elena L.}",

note = "This research was funded by the Russian Science Foundation (grant #19-74-30011) and project ICBFM SB RAS #121031300044-5",

year = "2024",

doi = "10.1016/j.biochi.2024.09.016",

language = "English",

journal = "Biochimie",

issn = "0300-9084",

publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Effect of immunostimulatory RNA on the fibrosis development in Bleomycin- or LPS-induced mouse models

AU - Sen'kova, Aleksandra V.

AU - Bishani, Ali

AU - Savin, Innokenty A.

AU - Zenkova, Marina A.

AU - Chernolovskaya, Elena L.

N1 - This research was funded by the Russian Science Foundation (grant #19-74-30011) and project ICBFM SB RAS #121031300044-5

PY - 2024

Y1 - 2024

N2 - Previously, we described a 19-base pair double-stranded RNA with 3′-trinucleotide overhangs, acting as immunostimulatory RNA (isRNA). This molecule demonstrated notable antiproliferative effects on cancer cells, inhibited tumor growth, and elicited immunostimulatory and antiviral responses by inducing cytokine and interferon production. Within this study, we compared the efficiency of lung fibrosis development, initiated in mice by BLM or LPS using different schemes of induction. Then we compared the effect of isRNA used in a preventive or therapeutic regimen on the development of fibrosis in selected BLM- and LPS-induced mouse models and showed that isRNA can be used in pathological conditions accompanied by the development of inflammation and the risk of fibrosis formation, without adverse side effects. Prophylactic regimen of isRNA application is beneficial for prevention of the development of pulmonary fibrosis.

AB - Previously, we described a 19-base pair double-stranded RNA with 3′-trinucleotide overhangs, acting as immunostimulatory RNA (isRNA). This molecule demonstrated notable antiproliferative effects on cancer cells, inhibited tumor growth, and elicited immunostimulatory and antiviral responses by inducing cytokine and interferon production. Within this study, we compared the efficiency of lung fibrosis development, initiated in mice by BLM or LPS using different schemes of induction. Then we compared the effect of isRNA used in a preventive or therapeutic regimen on the development of fibrosis in selected BLM- and LPS-induced mouse models and showed that isRNA can be used in pathological conditions accompanied by the development of inflammation and the risk of fibrosis formation, without adverse side effects. Prophylactic regimen of isRNA application is beneficial for prevention of the development of pulmonary fibrosis.

KW - Bleomycine

KW - Immunostimulatory RNA

KW - Inflammation

KW - LPS

KW - Pulmonary fibrosis

UR - https://www.scopus.com/record/display.uri?eid=2-s2.0-85205718105&origin=inward&txGid=7ec1d3fdd9e78dc5ea0933c31c88622b

UR - https://www.mendeley.com/catalogue/b132eef3-d601-34b7-bf27-38e7b06a1236/

U2 - 10.1016/j.biochi.2024.09.016

DO - 10.1016/j.biochi.2024.09.016

M3 - Article

C2 - 39362399

JO - Biochimie

JF - Biochimie

SN - 0300-9084

ER -

ID: 61307746